Press release
Opioid Withdrawal Syndrome Market Size in the 7MM was valued ~USD 1,302 million in 2022 and is anticipated to grow at a significant CAGR by 2034, estimates DelveInsight
Opioid Withdrawal Syndrome Market
Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Opioid Withdrawal Syndrome Market Size- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Opioid Withdrawal Syndrome Market Report
• According to DelveInsight estimations, 9,077,124 Number of cases with long-term opioid usage were found in 2022 in the 7MM.
• As per DelveInsight's estimations, the total number of cases with opioid withdrawal syndrome in the United States were approximately 7,087,561 in 2022 and are projected to decrease during the forecast period.
• According to DelveInsight's estimates, the number of opioid misuse cases in EU4 and the UK were found to be approximately 1,365,293 in 2022.
• The leading Opioid withdrawal Syndrome Companies such as DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.
• Promising Opioid withdrawal Syndrome Therapies such as Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.
Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Opioid Withdrawal Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Opioid Withdrawal Syndrome Epidemiology Segmentation in the 7MM
• Number of Opioid misuse cases
• Number of cases with long-term opioid usage
• Total Opioid Withdrawal Syndrome Cases
Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Prevalence- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Opioid Withdrawal Syndrome Marketed Drugs
• LUCEMYRA (lofexidine hydrochloride): US World Meds LLC
LUCEMYRA is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine. LUCEMYRA is not an opioid drug. While LUCEMYRA may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days. LUCEMYRA is not a treatment for OUD but can be used as part of a broader, long-term treatment plan for managing OUD. LUCEMYRA is under license from Britannia Pharmaceuticals, Ltd. USWM, LLC is the exclusive licensee and distributor of LUCEMYRA in the United States and Its territories.
Opioid Withdrawal Syndrome Emerging Drugs
• DMX-1002 (Ibogaine HCl): DemeRx IB, Inc. /atai Life Sciences
DMX-1002 is an oral formulation of ibogaine, an oneirogenic indole alkaloid with cholinergic, glutamatergic, and monoaminergic receptor modulatory activity. Ibogaine is a natural indole alkaloid derived from the West African iboga plant and has previously been marketed as a stimulant and antidepressant in France under the brand name Lambarène. Known for its oneirophrenic and hallucinogenic properties, uncontrolled data from hundreds of patients suggest that Ibogaine is effective as both an acute detoxifier and treatment for opioid addiction. At present, DMX-1002 is in Phase I/II of clinical development for the treatment of Withdrawal Syndrome. As per the DemeRx pipeline, the drug is being developed for opioid withdrawal management and relapse prevention, whereas as per atai Life Sciences pipeline, the drug is being developed for OUD treatment.
• MN-166: Medicinova
MN-166 is a first in class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago.
Discover the future of Opioid Withdrawal Syndrome treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Opioid Withdrawal Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Opioid Withdrawal Syndrome Market Outlook
The treatment approach for Opioid Withdrawal Syndrome depends on the severity of the symptoms experienced by the individual. In cases of mild withdrawal, patients are encouraged to prioritize hydration by consuming at least 2-3 L of water daily and may benefit from supplementation with vitamins B and C to support overall health. Typically, symptomatic treatment and supportive care suffice for managing mild symptoms, focusing on alleviating discomfort and ensuring the patient's well-being during this phase.
Scope of the Opioid Withdrawal Syndrome Market Report
Coverage- 7MM
Study Period- 2020-2034
Opioid withdrawal Syndrome Companies- DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.
Opioid withdrawal Syndrome Therapies such as Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.
From market size to emerging drugs-find it all in our latest report. Read now! @ Opioid Withdrawal Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Opioid Withdrawal Syndrome Market Overview at a Glance
4. Opioid Withdrawal Syndrome Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Opioid Withdrawal Syndrome: Disease Background and Overview
8. Opioid Withdrawal Syndrome Epidemiology and Patient Population
9. Patient Journey
10. Opioid Withdrawal Syndrome Marketed Drugs
11. Opioid Withdrawal Syndrome Emerging Drugs
12. Opioid Withdrawal Syndrome: Market Analysis
13. Key Opinion Leaders' Views
14. Opioid Withdrawal Syndrome SWOT Analysis
15. Opioid Withdrawal Syndrome Unmet Needs
16. Opioid Withdrawal Syndrome Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Opioid Withdrawal Syndrome Market Size in the 7MM was valued ~USD 1,302 million in 2022 and is anticipated to grow at a significant CAGR by 2034, estimates DelveInsight here
News-ID: 4245547 • Views: …
More Releases from DelveInsight Business Research LLP
Netherton Syndrome Treatment Market Size in the 7MM was valued at ~USD 25 millio …
DelveInsight's "Netherton Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Netherton Syndrome, historical and forecasted epidemiology as well as the Netherton Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Unlock key insights into the Netherton Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Netherton Syndrome Market Size-…
Nephrotic Syndrome Treatment Market Size in the 7MM reached ~USD 401 million in …
DelveInsight's "Nephrotic Syndrome Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Nephrotic Syndrome, historical and forecasted epidemiology, and the Nephrotic Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Nephrotic Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Nephrotic Syndrome Market Size-…
Leptomeningeal Metastases Market Size in 7MM was ~USD 1700 Million in 2024 and w …
DelveInsight's " Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology, as well as the Leptomeningeal Metastases Market Trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Leptomeningeal Metastases Market with DelveInsight's In-Depth Report @ Leptomeningeal Metastases Treatment Market Size- https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Leptomeningeal…
Interstitial Cystitis Market Size in 7MM was ~USD 3 Billion in 2024 and it is ex …
DelveInsight's " Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Interstitial Cystitis, historical and forecasted epidemiology, as well as the Interstitial Cystitis Market Trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Interstitial Cystitis Market with DelveInsight's In-Depth Report @ Interstitial Cystitis Treatment Market Size- https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Interstitial…
More Releases for Opioid
Rising Opioid Use For Pain Management Fuels Growth In Opioid-Induced Constipatio …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Opioid-Induced Constipation Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treatment of opioid-induced constipation has seen a substantial growth recently. It is expected to escalate from a solid $1.78 billion in 2024 to an impressive $1.9 billion in 2025, exhibiting…
Growing Number Of Opioid Addiction Cases: Strategic Insights Driving Opioid Use …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Opioid Use Disorder (OUD) Market Size By 2025?
The market size for opioid use disorder (OUD) has experienced a quick expansion in the past few years. The growth is projected to rise from $3.96 billion in 2024 to $4.39 billion in 2025, boasting a compound…
Key Influencer in the Opioid-Induced Constipation Treatment Market 2025: Rising …
What combination of drivers is leading to accelerated growth in the opioid-induced constipation treatment market?
The rise in opioid administration for cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market. Opioids are commonly used for managing moderate to severe pain, but they can cause constipation. OIC treatments are vital for improving the quality of life for patients on opioids, allowing them to maintain…
Top Factor Driving Opioid Use Disorder (OUD) Market Growth in 2025: Growing Numb …
How Are the key drivers contributing to the expansion of the opioid use disorder (oud) market?
The rise in instances of opioid dependency is set to fuel the expansion of the opioid use disorder (OUD) market. Opioid dependency defines a health concern marked by habitual and uncontrolled opioid consumption which negatively impacts health. These opioids can generate feelings of bliss and relief from pain, but continued usage often results in tolerance…
What's Driving the Opioid-Induced Constipation Treatment Market 2025-2034: Risin …
What Are the Projections for the Size and Growth Rate of the Opioid-Induced Constipation Treatment Market?
The market size for treatments of constipation caused by opioids has seen robust growth lately. The forecasted growth indicates an increase from $1.78 billion in 2024 to $1.9 billion in 2025, representing a compound annual growth rate (CAGR) of 7.0%. This past growth is associated with a growing elderly population, individualized treatments for OIC, the…
MEDICAL MARIJUANA AND THE OPIOID CRISIS
Marijuana from the Cannabis plant is classified as a psychoactive drug used for medical or recreational purposes. Although it has been used for decades, in the U.S., it is still illegal under federal law to use and possess marijuana.
Get PDF Sample Brochure of this report at: https://decisionmarketreports.com/request-sample/1247622
Nevertheless, at the state level, policies regarding the medical and recreational use of Cannabis vary greatly, and in many states conflict significantly with federal…
